Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.
2.

A convergent synthesis of the 11-oxa prostaglandin analogue AL-12182.

Fox ME, Jackson M, Lennon IC, McCague R.

J Org Chem. 2005 Feb 18;70(4):1227-36.

PMID:
15704955
3.

Asymmetric hydrogenation of a 4,4-diaryl-3-butenoate; a novel approach to sertraline.

Boulton LT, Lennon IC, McCague R.

Org Biomol Chem. 2003 Apr 7;1(7):1094-6.

PMID:
12926379
4.

A thermostable L-aminoacylase from Thermococcus litoralis: cloning, overexpression, characterization, and applications in biotransformations.

Toogood HS, Hollingsworth EJ, Brown RC, Taylor IN, Taylor SJ, McCague R, Littlechild JA.

Extremophiles. 2002 Apr;6(2):111-22.

PMID:
12013431
5.

Metal- and Ligand-Accelerated Catalysis of the Baylis-Hillman Reaction.

Aggarwal VK, Mereu A, Tarver GJ, McCague R.

J Org Chem. 1998 Oct 16;63(21):7183-7189.

PMID:
11672359
6.

Structure-activity relationships for triphenylethylene antiestrogens on hepatic phase-I and phase-II enzyme expression.

Nuwaysir EF, Dragan YP, McCague R, Martin P, Mann J, Jordan VC, Pitot HC.

Biochem Pharmacol. 1998 Aug 1;56(3):321-7.

PMID:
9744569
7.

Crystallization and preliminary X-ray studies on Candida cylindracea lipase.

Lewis G, Bevan J, Rawas A, McMichael P, Wisdom R, McCague R, Watson H, Littlechild J.

Acta Crystallogr D Biol Crystallogr. 1997 May 1;53(Pt 3):348-51.

PMID:
15299945
8.

The synthesis of (R)-(+)-lipoic acid using a monooxygenase-catalysed biotransformation as the key step.

Adger B, Bes MT, Grogan G, McCague R, Pedragosa-Moreau S, Roberts SM, Villa R, Wan PW, Willetts AJ.

Bioorg Med Chem. 1997 Feb;5(2):253-61.

PMID:
9061190
9.

The effect of tamoxifen and two of its non-isomerizable fixed-ring analogs on multistage rat hepatocarcinogenesis.

Dragan YP, Fahey S, Nuwaysir E, Sattler C, Babcock K, Vaughan J, McCague R, Jordan VC, Pitot HC.

Carcinogenesis. 1996 Mar;17(3):585-94.

PMID:
8631149
10.

Esters of 3-pyridylacetic acid that combine potent inhibition of 17 alpha-hydroxylase/C17,20-lyase (cytochrome P45017 alpha) with resistance to esterase hydrolysis.

Rowlands MG, Barrie SE, Chan F, Houghton J, Jarman M, McCague R, Potter GA.

J Med Chem. 1995 Oct 13;38(21):4191-7.

PMID:
7473546
11.

Comparison between inhibition of protein kinase C and antagonism of calmodulin by tamoxifen analogues.

Rowlands MG, Budworth J, Jarman M, Hardcastle IR, McCague R, Gescher A.

Biochem Pharmacol. 1995 Aug 25;50(5):723-6.

PMID:
7669076
12.

The deuterium isotope effect for the alpha-hydroxylation of tamoxifen by rat liver microsomes accounts for the reduced genotoxicity of [D5-ethyl]tamoxifen.

Jarman M, Poon GK, Rowlands MG, Grimshaw RM, Horton MN, Potter GA, McCague R.

Carcinogenesis. 1995 Apr;16(4):683-8.

PMID:
7728943
13.

Idoxifene: report of a phase I study in patients with metastatic breast cancer.

Coombes RC, Haynes BP, Dowsett M, Quigley M, English J, Judson IR, Griggs LJ, Potter GA, McCague R, Jarman M.

Cancer Res. 1995 Mar 1;55(5):1070-4.

14.

Identification of tamoxifen metabolites in human Hep G2 cell line, human liver homogenate, and patients on long-term therapy for breast cancer.

Poon GK, Walter B, Lønning PE, Horton MN, McCague R.

Drug Metab Dispos. 1995 Mar;23(3):377-82.

PMID:
7628304
15.
16.
17.

A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism.

Potter GA, McCague R, Jarman M.

Carcinogenesis. 1994 Mar;15(3):439-42.

PMID:
8118925
18.

The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth.

Osborne CK, Jarman M, McCague R, Coronado EB, Hilsenbeck SG, Wakeling AE.

Cancer Chemother Pharmacol. 1994;34(2):89-95.

PMID:
8194171
19.

Analysis of phase I and phase II metabolites of tamoxifen in breast cancer patients.

Poon GK, Chui YC, McCague R, Lłnning PE, Feng R, Rowlands MG, Jarman M.

Drug Metab Dispos. 1993 Nov-Dec;21(6):1119-24.

PMID:
7905393
20.

Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites.

Wolf DM, Langan-Fahey SM, Parker CJ, McCague R, Jordan VC.

J Natl Cancer Inst. 1993 May 19;85(10):806-12.

PMID:
8487325
23.

On-line continuous-flow dialysis thermospray tandem mass spectrometry for quantitative screening of drugs in plasma: rogletimide.

van Bakergem E, van der Hoeven RA, Niessen WM, Tjaden UR, van der Greef J, Poon GK, McCague R.

J Chromatogr. 1992 May 15;598(2):189-94.

PMID:
1618979
24.

Identification of 4-hydroxyandrost-4-ene-3,17-dione metabolites in prostatic cancer patients by liquid chromatography-mass spectrometry.

Poon GK, Jarman M, McCague R, Davies JH, Heeremans CE, van der Hoeven RA, Niessen WM, van der Greef J.

J Chromatogr. 1992 May 8;576(2):235-44.

PMID:
1400711
25.

Characterisation of metabolites of 3-ethyl-3-(4-pyridyl)-piperidine-2,6-dione, a potential breast cancer drug.

Poon GK, McCague R, Griggs LJ, Jarman M, Lewis IA.

J Chromatogr. 1991 Dec 6;572(1-2):143-57.

PMID:
1818050
26.

Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer.

Chander SK, McCague R, Luqmani Y, Newton C, Dowsett M, Jarman M, Coombes RC.

Cancer Res. 1991 Nov 1;51(21):5851-8.

27.

Effect of estrogenic and antiestrogenic triphenylethylene derivatives on progesterone and estrogen receptors levels of MCF-7 cells.

Legros N, Leclercq G, McCague R.

Biochem Pharmacol. 1991 Oct 9;42(9):1837-41. No abstract available.

PMID:
1930303
28.
30.
31.

Inhibition of enzymes of estrogen and androgen biosynthesis by esters of 4-pyridylacetic acid.

McCague R, Rowlands MG, Barrie SE, Houghton J.

J Med Chem. 1990 Nov;33(11):3050-5.

PMID:
2231604
33.

Hydroxyperfluoroazobenzenes: novel inhibitors of enzymes of androgen biosynthesis.

Jarman M, Barrie SE, Deadman JJ, Houghton J, McCague R, Rowlands MG.

J Med Chem. 1990 Sep;33(9):2452-5.

PMID:
2391687
34.

Variation of the inhibition of calmodulin dependent cyclic AMP phosphodiesterase amongst analogues of tamoxifen; correlations with cytotoxicity.

Rowlands MG, Parr IB, McCague R, Jarman M, Goddard PM.

Biochem Pharmacol. 1990 Jul 15;40(2):283-9.

PMID:
2165403
35.

Metabolism of tamoxifen by isolated rat hepatocytes. Identification of the glucuronide of 4-hydroxytamoxifen.

McCague R, Parr IB, Leclercq G, Leung OT, Jarman M.

Biochem Pharmacol. 1990 May 1;39(9):1459-65.

PMID:
2334445
36.

Derivatives of tamoxifen. Dependence of antiestrogenicity on the 4-substituent.

McCague R, Leclercq G, Legros N, Goodman J, Blackburn GM, Jarman M, Foster AB.

J Med Chem. 1989 Dec;32(12):2527-33.

PMID:
2585441
37.

Octafluorotoluene as a derivatizing agent for steroids in human plasma.

Baker MH, Howe I, Jarman M, McCague R.

Biomed Environ Mass Spectrom. 1988 Oct;16(1-12):211-3.

PMID:
3242672
38.

Non-isomerisable antiestrogens related to tamoxifen.

McCague R, Jarman M, Leung OT, Foster AB, Leclercq G, Stoessel S.

J Steroid Biochem. 1988 Oct;31(4B):545-7.

PMID:
3199805
40.

Ligand interaction at the estrogen receptor to program antiestrogen action: a study with nonsteroidal compounds in vitro.

Jordan VC, Koch R, Langan S, McCague R.

Endocrinology. 1988 Apr;122(4):1449-54.

PMID:
3345720
43.

The inhibitory effect of p-trifluoromethyl substitution on the hepatic microsomal metabolism of benzyl phenyl sulphide.

Seago A, Houghton J, McCague R, Foster AB, Coe PL, Falshaw A.

Biochem Pharmacol. 1987 Feb 1;36(3):400-3. No abstract available.

PMID:
3814182
44.

Modification of the basic side chain in tamoxifen: effects on microsomal metabolism and in vitro biological activity.

Foster AB, McCague R, Seago A, Leclercq G, Stoessel S, Roy F.

Anticancer Drug Des. 1986 Nov;1(3):245-57.

PMID:
3450297
47.

Hydroxy derivatives of tamoxifen.

Foster AB, Jarman M, Leung OT, McCague R, Leclercq G, Devleeschouwer N.

J Med Chem. 1985 Oct;28(10):1491-7.

PMID:
4045924

Supplemental Content

Loading ...
Support Center